A 56-year-old female was referred to the Royal Brisbane Hospital for consideration of further management of chronic, refractory autoimmune thrombocytopenic purpura ( The patient remains well 13 months post-transplant with a platelet count 4200 Â 10 9 /l, with a view towards proceeding to bilateral total hip replacements.
We report successful attainment of remission from chronic refractory ITP utilising nonablative stem-cell transplantation. Less than optimal response rates are achievable with currently available therapeutic options for ITP. High-dose therapy with autologous stem-cell transplantation has been performed. 1 Response rates have been generally poor, and duration of responses has been short. Reports of incidental resolution of autoimmune diseases following allogeneic stem cell transplantation for haematological malignancy and therapy-related severe aplastic anaemia exist. 2, 3 The existence of a 'graft-versus-autoimmunity' effect was hypothesised, analogous to the welldescribed graft-versus-tumour effect.
Concerns have been raised about the use of intensive chemo-radiotherapy in the setting of severe thrombocytopenia. A previous report documents an abrupt increase in bleeding diathesis in a 19-year-old female undergoing autologous stem-cell mobilisation utilising cyclophosphamide and G-CSF unfortunately leading to death from intracranial haemorrhage. 4 It was postulated that inhibition of hyperactive haematopoiesis without decrease in autoimmune destruction contributed to this evolution from a stable basal situation. We considered that the choice of a nonmyeloablative conditioning protocol in our patient would minimise end-organ toxicity, and therefore risk of haemorrhage. Additionally, we administered multidonor platelets pre-emptively for platelet counts on any day o20 Â 10 9 /l. No bleeding episodes were experienced. Two prior reports of complete remission obtained through stem cell transplantation for Evans syndrome are available. 5, 6 No prior reports of successful transplantation of chronic, refractory ITP are in evidence. It is unlikely that the immunosuppressive effect of the conditioning regimen contributed to the delayed platelet response. The prior lack of response to cyclosporin, and the onset of platelet increment following cessation of cyclosporin, make it unlikely that the response was related to GVHD prophylaxis. A temporal association existed with de novo onset of limited stage chronic GVHD and the rise in platelet count.
Furthermore, from studies of transplants utilising ABO major-mismatched donor-recipients, isohaemagluttinins are documented to persist for up to 6 months posttransplant. 7 Time to clearance of antiplatelet antibodies is likely to be similar. 
